GlassScriptPhysician profile
Thomas U Tuten
NPI 1407906035
$2,122.18
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $794 · 2021: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $1,614.15 | 2019-2020 | |
| Cook Medical LLC | $138.71 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $112.73 | 2019-2021 | |
| Penumbra, INC. | $67.50 | 2019 | |
| Amgen INC. | $22.61 | 2020 | |
| Siemens Medical Solutions USA, INC. | $17.50 | 2020 | |
| Clovis Oncology, INC. | $15.05 | 2020 | |
| Seagen INC. | $13.19 | 2019 | |
| Janssen Biotech, INC. | $12.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.40 | 2019 | |
| Canon Medical Systems USA, INC. | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tuten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.